Lucid Diagnostics (LUCD) Expected to Announce Earnings on Monday

Lucid Diagnostics (NASDAQ:LUCD) is expected to be releasing its earnings data before the market opens on Monday, March 24th. Analysts expect Lucid Diagnostics to post earnings of ($0.15) per share and revenue of $1.42 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Lucid Diagnostics Stock Down 3.2 %

Shares of LUCD stock opened at $1.52 on Friday. Lucid Diagnostics has a 12 month low of $0.63 and a 12 month high of $1.63. The firm has a market cap of $90.20 million, a PE ratio of -1.33 and a beta of 1.34. The stock has a 50 day moving average of $1.20 and a 200-day moving average of $0.98.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets cut their price target on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a report on Monday, December 9th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $3.63.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.